Business Context and Reporting Period
The filing is an unaudited Form 10-Q for the quarter and six months ended June 30, 2022, filed August 4, 2022. The source document identifies the registrant as Aeglea BioTherapeutics, Inc. (Nasdaq: AGLE), not Spyre Therapeutics, Inc.; this company identity should be verified.
Aeglea is a clinical-stage biotechnology company developing engineered human enzyme therapies for rare metabolic diseases. Lead programs include pegzilarginase for Arginase 1 Deficiency, AGLE-177 for Homocystinuria, and preclinical AGLE-325 for Cystinuria. The company has no approved products and has not generated product-sales revenue.
Financial and Operating Metrics
| Metric | Q2 2022 | Q2 2021 | Six months 2022 | Six months 2021 |
|---|---|---|---|---|
| Total revenue | $0.6 million | $13.7 million | $2.0 million | $13.7 million |
| Research and development expense | $15.4 million | $13.6 million | $32.4 million | $25.4 million |
| General and administrative expense | $7.7 million | $6.8 million | $16.5 million | $13.2 million |
| Loss from operations | $(22.4) million | $(6.7) million | $(46.9) million | $(24.9) million |
| Net loss | $(22.3) million | $(6.8) million | $(46.8) million | $(25.0) million |
| Net loss per share | $(0.27) | $(0.10) | $(0.63) | $(0.38) |
| Operating cash flow | Not separately provided | Not separately provided | $(46.9) million | $(17.4) million |
- Revenue consisted of development fees under the Immedica license agreement; no product revenue was recorded. Because revenue was minimal relative to operating expenses, operating and net margins were deeply negative and not economically meaningful.
- At June 30, 2022, cash and cash equivalents were $37.5 million, marketable securities were $51.1 million, and restricted cash was $1.8 million, totaling $90.4 million of cash, cash equivalents, marketable securities and restricted cash.
- Working capital was $80.8 million and accumulated deficit was $388.6 million.
- Total liabilities were $22.6 million. The company reported no debt or credit facility; liabilities primarily consisted of operating leases, accrued obligations and deferred revenue.
- Cash flow from investing activities was positive $26.5 million, principally reflecting net maturities and sales of marketable securities. Financing activities provided $42.8 million.
- Common shares outstanding increased from 49.4 million at December 31, 2021 to 61.2 million at June 30, 2022. The company also had 32.98 million pre-funded warrants outstanding at June 30, 2022, creating substantial potential dilution.
Material Changes Versus the Prior Comparable Period
- Six-month revenue fell 85% to $2.0 million from $13.7 million because the prior-year period included $12.0 million of license revenue from Immedica; 2022 revenue consisted only of development-fee recognition.
- Six-month research and development expense increased 27% to $32.4 million, driven by BLA preparation, continued PEACE Phase 3 activities, AGLE-177 enrollment and AGLE-325 IND-enabling work, along with higher personnel costs.
- Six-month general and administrative expense increased 25% to $16.5 million, reflecting increased commercialization infrastructure and personnel costs.
- Six-month net loss increased 87% to $46.8 million, while operating cash burn increased to $46.9 million from $17.4 million.
- In May 2022, the company raised approximately $42.9 million of net proceeds through a registered direct offering of common stock and pre-funded warrants.
- Marketable securities declined to $51.1 million from $78.0 million at year-end 2021, while cash and cash equivalents increased to $37.5 million from $15.1 million.
Guidance, Outlook, Risks and Unusual Items
- Management stated that existing cash, cash equivalents and marketable securities were expected to fund operations through the second quarter of 2023. The company nevertheless concluded that substantial doubt exists about its ability to continue as a going concern within twelve months of issuance because of recurring losses and the need for additional financing.
- The company expects continued operating losses and increasing expenses as it advances pegzilarginase and AGLE-177, prepares for potential commercialization, and develops AGLE-325. No formal revenue or earnings guidance was provided.
- On June 2, 2022, the FDA issued a Refusal to File for the pegzilarginase BLA. The FDA requested additional evidence supporting effectiveness, including evidence linking plasma arginine and metabolite reduction to clinical benefit or clinical data showing treatment effects on meaningful outcomes, as well as additional chemistry, manufacturing and controls information. No safety issue was identified in the letter.
- The FDA had previously indicated that the PEACE Phase 3 results were promising but hypothesis-generating and that an additional randomized placebo-controlled trial longer than 24 weeks might be required. The company continues discussions with the FDA regarding a path to BLA resubmission.
- Management reported positive biochemical results for pegzilarginase, including a 76.7% reduction in mean plasma arginine versus placebo and normal arginine levels in 90.5% of treated patients, but several mobility endpoints did not achieve nominal statistical significance.
- AGLE-177 was advancing through a Phase 1/2 trial; the company expected initial clinical data in the fourth quarter of 2022. AGLE-325 IND-enabling and manufacturing activities were partly postponed because of raw-material and capital constraints.
- COVID-19 continued to affect patient screening, dosing, enrollment, site operations, manufacturing supply chains and regulatory timelines. The company also cited dependence on contract research and manufacturing organizations, clinical and regulatory uncertainty, competition, intellectual-property risks and potential future equity dilution.
- The company disclosed a Nasdaq minimum-bid-price deficiency notice received July 18, 2022, with an initial compliance period ending January 16, 2023. Failure to regain compliance could result in delisting, subject to potential extension and other requirements.
- Future minimum lease commitments through April 2028 were $6.7 million. No material legal proceedings were reported.
Important Facts for Investors to Verify
- Confirm that this filing belongs to Aeglea BioTherapeutics, Inc. rather than Spyre Therapeutics, Inc.
- Review the FDA Refusal to File and the company’s proposed regulatory path, including whether an additional randomized trial is required.
- Assess financing needs after the stated second-quarter 2023 cash runway and the likelihood, terms and dilution from future capital raises.
- Reconcile common shares outstanding with the 32.98 million outstanding pre-funded warrants and the additional shares available under the at-the-market program.
- Track AGLE-177 clinical data, PEACE extension-study results, AGLE-325 funding and manufacturing progress, and the effect of COVID-19-related delays.
- Monitor Nasdaq bid-price compliance and any resulting reverse split, listing transfer or delisting risk.